Biomarker Research

Article	Citations
Metabolic reprogramming in macrophage responses	261
Biomarkers for cancer-associated fibroblasts	167
miR-21: a non‐specific biomarker of all maladies	144
Recent advances in systemic therapy for hepatocellular carcinoma	116
The landscape of bispecific T cell engager in cancer treatment	114
Targeting ferroptosis in breast cancer	104
CAR-NK cells for cancer immunotherapy: from bench to bedside	94
A comprehensive comparison between camelid nanobodies and single chain variable fragments	93
Biological roles of RNA m5C modification and its implications in Cancer immunotherapy	87
Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study	78
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion	74
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	73
Imaging biomarkers for evaluating tumor response: RECIST and beyond	69
Nanobody-based CAR-T cells for cancer immunotherapy	66
Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues	65
Detection of circulating tumor cells: opportunities and challenges	64
Immunotherapy in endometrial cancer: rationale, practice and perspectives	62
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	62
Alternative Polyadenylation: a new frontier in post transcriptional regulation	60
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma	57
The role of ferroptosis in lung cancer	57
Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment	53
Cancer-associated adipocytes as immunomodulators in cancer	53
Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma	52
The role of biomarkers in personalized immunotherapy	51

Targeting interleukin-1β and inflammation in lung cancer	50
Prolonged elevation of serum neurofilament light after concussion in male Australian football players	49
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy	49
Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia	48
p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors	47
The role of phosphatidylserine on the membrane in immunity and blood coagulation	46
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis	46
Risk factors for immune-related adverse events: what have we learned and what lies ahead?	44
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed	42
The landscape overview of CD47-based immunotherapy for hematological malignancies	41
TOX as a potential target for immunotherapy in lymphocytic malignancies	39
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives	38
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives	38
Intratumor microbiome in cancer progression: current developments, challenges and future trends	38
Metastasis-associated fibroblasts: an emerging target for metastatic cancer	37
Clinical translation of patient-derived tumour organoids- bottlenecks and strategies	36
Dysregulated bile acid receptor-mediated signaling and IL-17A induction are implicated in diet-associated hepatic health and cognitive function	36
Current views on the genetic landscape and management of variant acute promyelocytic leukemia	36
Targeting neoantigens for cancer immunotherapy	36
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment	36
E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors	33
Current challenges and best practices for cell-free long RNA biomarker discovery	32
The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy	31
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer	31
N6-methyladenine modification in noncoding RNAs and its function in cancer	30
Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy	30
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer	29
Advances of cancer-associated fibroblasts in liver cancer	29
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis	29
Detection and clinical significance of circulating tumor cells in colorectal cancer	28
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy	28
Strategies to enhance CAR-T persistence	28
The emerging role of RNA N6-methyladenosine methylation in breast cancer	27
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer	27
Recent updates on Sintilimab in solid tumor immunotherapy	27
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance	26
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma	26
MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer	26
LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma	26
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges	25
Nucleases as molecular targets for cancer diagnosis	24
The significant role of redox system in myeloid leukemia: from pathogenesis to therapeutic applications	24
Extrachromosomal circular DNA (eccDNA): an emerging star in cancer	24
Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?	24
CAR-T cell potency: from structural elements to vector backbone components	24
Advances in the DNA methylation hydroxylase TET1	24
Cancer metabolites: promising biomarkers for cancer liquid biopsy	24
Current and emerging therapies for primary central nervous system lymphoma	24
HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma	23
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma	23

The intriguing roles of Siglec family members in the tumor microenvironment	23
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse	22
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies	22
Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma	22
Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	21
A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer	21
MiR-124-3p impedes the metastasis of non-small cell lung cancer via extracellular exosome transport and intracellular PI3K/AKT signaling	21
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors	20
Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia	19
MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions	19
Effect of regulatory cell death on the occurrence and development of head and neck squamous cell carcinoma	18
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers	18
Sintilimab for the treatment of non-small cell lung cancer	18
An analysis of the role of HnRNP C dysregulation in cancers	18
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives	18
Novel strategies for immuno-oncology breakthroughs with cell therapy	18
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response	18
Research and application of single-cell sequencing in tumor heterogeneity and drug resistance of circulating tumor cells	18
The role of pyroptosis in modulating the tumor immune microenvironment	18
Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma	17
Cervical cancer heterogeneity: a constant battle against viruses and drugs	17
Multifaced roles of PLAC8 in cancer	17
The biology of YAP in programmed cell death	17
The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma	17
Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy	16
FAM83A is a potential biomarker for breast cancer initiation	16
Molecular mechanisms and clinical applications of exosomes in prostate cancer	16
Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma	16
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	16
The application of Aptamer in biomarker discovery	16
New cell sources for CAR-based immunotherapy	16
The function and clinical implication of YTHDF1 in the human system development and cancer	15
KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors	15
Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow	14
Emerging treatment modalities for systemic therapy in hepatocellular carcinoma	14
Minimal residual disease in multiple myeloma: current status	14
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives	14
Oncolytic viruses for triple negative breast cancer and beyond	14
Review immune response of targeting CD39 in cancer	14
Donor T cells for CAR T cell therapy	14
The emerging landscape of exosomal CircRNAs in solid cancers and hematological malignancies	13
HER2-targeted therapies in cancer: a systematic review	13
METTL1 promotes neuroblastoma development through m7G tRNA modification and selective oncogenic gene translation	13
The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?	13
A DNA methylation-based test for esophageal cancer detection	13
Biomarkers for immune checkpoint inhibition in sarcomas – are we close to clinical implementation?	13
EIF4A3-induced Circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p/RNF113A pathway	13
Exosome derived from tumor-associated macrophages: biogenesis, functions, and therapeutic implications in human cancers	13
Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction	12
The lncRNA TEX41 is upregulated in pediatric B-Cells Acute Lymphoblastic Leukemia and it is necessary for leukemic cell growth	12
ZG16 promotes T-cell mediated immunity through direct binding to PD-L1 in colon cancer	12
Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients	12
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives	12
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges	12
Selective isolation of extracellular vesicles from minimally processed human plasma as a translational strategy for liquid biopsies	12
Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer	12
Plasma contact factors as novel biomarkers for diagnosing Alzheimer’s disease	12
Oncogenic alterations in advanced NSCLC: a molecular super-highway	12
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma	12
Circular RNA circEMB promotes osteosarcoma progression and metastasis by sponging miR-3184-5p and regulating EGFR expression	11
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia	11
SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma	11
MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study	11
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo	11
New insights into the function of Interleukin-25 in disease pathogenesis	11
Application and prospects of single cell sequencing in tumors	11
Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected	11
LncRNAs serve as novel biomarkers for diagnosis and prognosis of childhood ALL	11
Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer	11
Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risks and benefits	11
Biomarkers as targets for CAR-T/NK cell therapy in AML	11
circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3	11
Modulation of the TGF-β signaling pathway by long noncoding RNA in hepatocellular carcinoma	11
Targeted proteomics-derived biomarker profile develops a multi-protein classifier in liquid biopsies for early detection of esophageal squamous cell carcinoma from a population-based case-control stud	11
Deubiquitinases in hematological malignancies	11
Functions of RNA N6-methyladenosine modification in acute myeloid leukemia	11
Tumor reversion: a dream or a reality	11
The Wnt/β-catenin signalling pathway in Haematological Neoplasms	10
Bioinformatics tools and data resources for assay development of fluid protein biomarkers	10
Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients	10

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML	10
Development of a novel BRCAness score that predicts response to PARP inhibitors	10
MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures	9
Advances in technology and applications of nanoimmunotherapy for cancer	9
Targeting TIGIT for cancer immunotherapy: recent advances and future directions	9
Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy	9
Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities	9
Novel insights into the multifaceted roles of m6A-modified LncRNAs in cancers: biological functions and therapeutic applications	9
The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study	9
The contribution of single-cell analysis of acute leukemia in the therapeutic strategy	9
Lower BCL11B expression is associated with adverse clinical outcome for patients with myelodysplastic syndrome	9
Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications	9
The role of YAP1 in liver cancer stem cells: proven and potential mechanisms	9
Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies	9
The role and regulation of Maf proteins in cancer	9
Accurate detection of early-stage lung cancer using a panel of circulating cell-free DNA methylation biomarkers	9
Key regulators of sensitivity to immunomodulatory drugs in cancer treatment	9
Brush swab as a noninvasive surrogate for tissue biopsies in epigenomic profiling of oral cancer	8
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer	8
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 tr	8
Lectins as potential tools for cancer biomarker discovery from extracellular vesicles	8
IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy	8
The role and metabolic adaptations of neutrophils in premetastatic niches	8
Novel role of immune-related non-coding RNAs as potential biomarkers regulating tumour immunoresponse via MICA/NKG2D pathway	8
Identification of exosomal microRNA panel as diagnostic and prognostic biomarker for small cell lung cancer	8
Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies	8
A novel 3-miRNA network regulates tumour progression in oral squamous cell carcinoma	8
Application of double-negative T cells in haematological malignancies: recent progress and future directions	8
Model integrating CT-based radiomics and genomics for survival prediction in esophageal cancer patients receiving definitive chemoradiotherapy	8
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer	8
LncRNA AC006064.4–201 serves as a novel molecular marker in alleviating cartilage senescence and protecting against osteoarthritis by destabilizing CDKN1B mRNA via interacting with PTBP1	8
Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies	8
Circulating MicroRNAs predict glycemic improvement and response to a behavioral intervention	8
Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT/mTOR signaling	7
Development of acoustically isolated extracellular plasma vesicles for biomarker discovery in allogeneic hematopoietic stem cell transplantation	7
Functions of N6-methyladenosine in cancer metabolism: from mechanism to targeted therapy	7
Correction to: LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/ miR-324-3p-SIRT5 axis in lung adenocarcinoma	7
Therapeutic targeting of PFKFB3 and PFKFB4 in multiple myeloma cells under hypoxic conditions	7
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma	7
Emerging agents and regimens for polycythemia vera and essential thrombocythemia	7
Vitamin D activates FBP1 to block the Warburg effect and modulate blast metabolism in acute myeloid leukemia	7
The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses	7
Human induced-T-to-natural killer cells have potent anti-tumour activities	7
Deamidation-related blood biomarkers show promise for early diagnostics of neurodegeneration	7
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors	7
Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients	7
singleCellBase: a high-quality manually curated database of cell markers for single cell annotation across multiple species	7
The pivotal application of patient-derived organoid biobanks for personalized treatment of gastrointestinal cancers	7
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches	7
Mitochondrial transfer in hematological malignancies	7
Emerging role of the RNA-editing enzyme ADAR1 in stem cell fate and function	6
Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1–2 follicular lymphoma: a real-world multicenter study	6
High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma	6
Low expression of ZHX1 and ZHX2 impacts on the prognosis of chronic lymphocytic leukemia	6
5mC and H3K9me3 of TRAF3IP2 promoter region accelerates the progression of translocation renal cell carcinoma	6
S100A6: molecular function and biomarker role	6
Integrated models of blood protein and metabolite enhance the diagnostic accuracy for Non-Small Cell Lung Cancer	6
Diversity roles of CHD1L in normal cell function and tumorigenesis	6
Neutrophil extracellular traps primed intercellular communication in cancer progression as a promising therapeutic target	6
Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML	6
Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia	6
Identification of cerebral spinal fluid protein biomarkers in Niemann-Pick disease, type C1	6
Long noncoding RNA LIPH-4 promotes esophageal squamous cell carcinoma progression by regulating the miR-216b/IGF2BP2 axis	6
SRTdb: an omnibus for human tissue and cancer-specific RNA transcripts	6
Radiogenomic association of deep MR imaging features with genomic profiles and clinical characteristics in breast cancer	6